Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Search PHGKB:

Last Posted: Sep 30, 2022
spot light Highlights

The oral microbiome and lung cancer risk: An analysis of 3 prospective cohort studies
E Vogtman et al, JNCI, August 5, 2022

Previous studies suggested associations between the oral microbiome and lung cancer, but studies were predominantly cross-sectional and underpowered. Multiple oral microbial measures were prospectively associated with lung cancer risk in three US cohort studies with associations varying by smoking history and histologic subtype. The oral microbiome may offer new opportunities for lung cancer prevention.

CDC Awards $215 Million in Funding to Advance National Cancer Prevention and Control toward Cancer Moonshot Goals
CDC, June 8, 2022 Brand

This funding builds on investments CDC has made in a comprehensive, coordinated cancer prevention and control portfolio for more than 30 years. Funded programs will demonstrate how proven strategies advance health equity and build capacity in cancer prevention and control. Outcomes include improving the provision of clinical preventive services; facilitating planning among partners to promote evidence-based strategies in communities; and improving cancer surveillance.

Redefining precision cancer prevention to promote health equity.
Butler Eboneé N et al. Trends in cancer 2022 2

Precision cancer prevention as it is currently envisioned is a targeted, molecular-based approach to intercept carcinogenesis before cancer develops or before it becomes untreatable. Unfortunately, due to systemic biases, current precision cancer prevention interventions might not be effective in all populations, especially in minoritized communities. In addition, not all cancer risk is attributable to genetic or even biological factors, but includes social determinants of health (SDH). Here, we propose a broader framework for precision cancer prevention, anchored in optimizing the benefits to harms for all people.

Index case identification and outcomes of cascade testing in high-risk breast and colorectal cancer predisposition genes
M Abedalthagafi, EJHG, January 22, 2022

Identification of a cancer pathogenic variant variant in an index-case facilitates management strategies such as decisions around the extent of surgical management or targeted therapeutic strategies. It also defines the cancer prevention and early detection strategies in at-risk family members. Cascade screening also reassures non-carrier relatives, excluding them from intensive surveillance and at the same time, contributing to the cost-effectiveness of genetic testing for a wider population.

Disclaimer: Articles listed in the Public Health Genomics and Precision Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.